1. Biochemistry and Chemical Biology
Download icon

Evolution of an intricate J-protein network driving protein disaggregation in eukaryotes

  1. Nadinath B Nillegoda  Is a corresponding author
  2. Antonia Stank
  3. Duccio Malinverni
  4. Niels Alberts
  5. Anna Szlachcic
  6. Alessandro Barducci
  7. Paolo De Los Rios
  8. Rebecca C Wade  Is a corresponding author
  9. Bernd Bukau  Is a corresponding author
  1. University of Heidelberg, Germany
  2. Heidelberg Institute for Theoretical Studies, Germany
  3. École Polytechnique Fédérale de Lausanne, Switzerland
  4. Inserm, U1054, France
Research Article
  • Cited 25
  • Views 2,734
  • Annotations
Cite this article as: eLife 2017;6:e24560 doi: 10.7554/eLife.24560

Abstract

Hsp70 participates in a broad spectrum of protein folding processes extending from nascent chain folding to protein disaggregation. This versatility in function is achieved through a diverse family of J-protein cochaperones that select substrates for Hsp70. Substrate selection is further tuned by transient complexation between different classes of J-proteins, which expands the range of protein aggregates targeted by metazoan Hsp70 for disaggregation. We assessed the prevalence and evolutionary conservation of J-protein complexation and cooperation in disaggregation. We find the emergence of a eukaryote-specific signature for interclass complexation of canonical J-proteins. Consistently, complexes exist in yeast and human cells, but not in bacteria, and correlate with cooperative action in disaggregation in vitro. Signature alterations exclude some J-proteins from networking, which ensures correct J-protein pairing, functional network integrity and J-protein specialization. This fundamental change in J-protein biology during the prokaryote-to-eukaryote transition allows for increased fine-tuning and broadening of Hsp70 function in eukaryotes.

Article and author information

Author details

  1. Nadinath B Nillegoda

    Center for Molecular Biology, University of Heidelberg, Heidelberg, Germany
    For correspondence
    n.nillegoda@zmbh.uni-heidelberg.de
    Competing interests
    The authors declare that no competing interests exist.
  2. Antonia Stank

    Heidelberg Institute for Theoretical Studies, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Duccio Malinverni

    Laboratory of Statistical Biophysics, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  4. Niels Alberts

    Center for Molecular Biology, University of Heidelberg, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Anna Szlachcic

    Center for Molecular Biology, University of Heidelberg, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Alessandro Barducci

    Inserm, U1054, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1911-8039
  7. Paolo De Los Rios

    Laboratory of Statistical Biophysics, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  8. Rebecca C Wade

    Center for Molecular Biology, University of Heidelberg, Heidelberg, Germany
    For correspondence
    rebecca.wade@h-its.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5951-8670
  9. Bernd Bukau

    Center for Molecular Biology, University of Heidelberg, Heidelberg, Germany
    For correspondence
    bukau@zmbh.uni-heidelberg.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0521-7199

Funding

Deutsche Forschungsgemeinschaft (SFB1036 BU617/19-3)

  • Bernd Bukau

Alexander von Humboldt-Stiftung (NA)

  • Nadinath B Nillegoda

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Jeffery W Kelly, The Scripps Research Institute, United States

Publication history

  1. Received: December 22, 2016
  2. Accepted: May 12, 2017
  3. Accepted Manuscript published: May 15, 2017 (version 1)
  4. Accepted Manuscript updated: May 23, 2017 (version 2)
  5. Version of Record published: August 3, 2017 (version 3)
  6. Version of Record updated: August 8, 2017 (version 4)

Copyright

© 2017, Nillegoda et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,734
    Page views
  • 775
    Downloads
  • 25
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Joseph Shaw et al.
    Research Article Updated

    Since the 1960s, a single class of agent has been licensed targeting virus-encoded ion channels, or ‘viroporins’, contrasting the success of channel blocking drugs in other areas of medicine. Although resistance arose to these prototypic adamantane inhibitors of the influenza A virus (IAV) M2 proton channel, a growing number of clinically and economically important viruses are now recognised to encode essential viroporins providing potential targets for modern drug discovery. We describe the first rationally designed viroporin inhibitor with a comprehensive structure-activity relationship (SAR). This step-change in understanding not only revealed a second biological function for the p7 viroporin from hepatitis C virus (HCV) during virus entry, but also enabled the synthesis of a labelled tool compound that retained biological activity. Hence, p7 inhibitors (p7i) represent a unique class of HCV antiviral targeting both the spread and establishment of infection, as well as a precedent for future viroporin-targeted drug discovery.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Eric Franklin, Martin Jonikas
    Insight

    A mechanism for concentrating carbon dioxide has for the first time been successfully transferred into a species that lacks such a process.